TREAT-NMD Ethics Board (TEB)
The TREAT-NMD Ethics Board (TEB) identifies and examines ethical and social aspects of research taking place in the context of TREAT-NMD.
The TEB is a voluntary multidisciplinary group comprised of clinicians, scientists, parents, ethicists and legal academics, patients and representatives of parent organisations. The TEB works in a collegiate, collaborative and inclusive manner to provide ethical guidance and balanced opinion in order to enhance the excellence TREAT-NMD aspires to.
Membership of the TEB is voluntary and drawn from the initial TREAT-NMD partner network, interest groups and invited external members. Members with special expertise, patient representatives, and other relevant groups may be co-opted as necessary.
Elizabeth Vroom is founder and president of the Duchenne Parent Project Netherlands since 1995 and Chair and co-founder of the World Duchenne Organisation (UPPMD). She is the mother of an …Netherlands
Since Fabiola’s adopted son was diagnosed with Facioscapulohumeral Muscular Dystrophy in 2005, Fabiola became deeply involved in the world of neuromuscular diseases. In Italy, Fabiola has been an active member …Italy
Alesandra Ferlini is a professor in medical genetics, director of the Medical Genetics section at the University of Ferrara (Italy), and coordinator of the EU funded BIO-NMD project. Her experience …Italy
Dr. Jan Kirschner is coordinator of the TREAT-NMD Clinical Trial Coordination Centre (CTCC) based in Freiburg, Germany. Jan has been joint coordinator of the German network for neuromuscular disorders MD-NET …Germany
Thomas Sejersen holds positions as Professor in Neuropediatrics at the Department of Women’s and Children’s Health of Karolinska Institute and consultant paediatrician at the Astrid Lindgrens Barnsjukhus (Stockholm, Sweden).Sweden